InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.023 0.001 (4.55%)+
Announcement
Release
31 Oct 2025 8:37AM
Price at Release
$0.022
Full Release
download
Summary
In the September 2025 quarterly report, TrivarX Ltd highlighted significant advancements including the completion of a $4.2 million placement for expanding diagnostic capabilities, and the completion of a clinical trial with the US Department of Veterans Affairs for detecting Major Depressive Episodes using proprietary ECG technology, which showed promising sensitivity and specificity. The company also initiated acquisition discussions for Stabl-Im™, a breakthrough brain tumor imaging technology, aiming to broaden its diagnostic portfolio into the neuro-oncology market. As part of its strategy, TrivarX is focusing on non-invasive diagnostic solutions leveraging AI-driven technologies. Financially, the company reported $587,000 in cash reserves at the quarter's end and outlined plans to secure further funding.
Key Points
  • Completion of a $4.2 million placement to advance diagnostic capabilities.
  • Completion of a clinical trial with the US Department of Veterans Affairs to detect Major Depressive Episodes.
  • Interim trial results showed strong sensitivity and specificity for the diagnostic algorithm.
  • Acquisition discussions for Stabl-Im™, a novel brain tumor imaging technology, were initiated.
  • The Stabl-Im™ technology uses stable isotope labeling for early brain tumor detection.
  • TrivarX aims to expand its diagnostic portfolio into the neuro-oncology market.
  • Cash at the end of the quarter was $587,000, with plans to raise additional funds.
  • The company focused on diversifying its technology for both mental health and neuro-oncology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.